RPS6 and renal cell carcinoma: Interestingly, Selumetinib, a selective MEK1 inhibitor, was reported to enhance the antitumor activity of everolimusa against renal cell carcinoma by decreasing p-RPS6 and p-4E-BP1 dramatically, which caused G1 cell cycle arrest and preventing reactivation of AKT and ERK (45).